COVID-19 vaccines

EU advises vs AstraZeneca shot in people with rare blood condition

Reuters

This is AI generated summarization, which may have errors. For context, always refer to the full article.

EU advises vs AstraZeneca shot in people with rare blood condition

ADVICE. A vial of AstraZeneca coronavirus vaccine is seen at a vaccination centre in Westfield Stratford City shopping center, amid the outbreak of COVID-19, in London, Britain, on February 18, 2021.

Henry Nicholls/Reuters

The European Medicines Agency's safety committee says capillary leak syndrome must be added as a new side effect to labeling on AstraZeneca's vaccine

Europe’s drug regulator on Friday, June 11, advised against using AstraZeneca’s COVID-19 vaccine in people with a history of a rare bleeding condition and said it was looking into heart inflammation cases after inoculation with all coronavirus shots.

The European Medicines Agency’s (EMA) safety committee in its evaluation said that capillary leak syndrome must be added as a new side effect to labeling on AstraZeneca’s vaccine.

It is a condition in which blood leaks from the smallest of vessels into muscles and body cavities and is characterized by swelling and a drop in blood pressure.

The regulator first began looking into these cases in April and the recommendation adds to AstraZeneca’s woes after its vaccine has been dogged with problems, including a possible link to rare blood clotting issues.

Last month, the EMA had advised against using the second AstraZeneca shot for people with the clotting conditions.

The watchdog is also broadening its probe into cases of myocarditis and pericarditis following inoculation with AstraZeneca’s vaccine and other shots from Pfizer, Moderna and J&J. – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.

Summarize this article with AI

How does this make you feel?

Loading
Download the Rappler App!